MedPath

Foley's Catheter Balloon Plus Tranexamic Acid During Cesarean Delivery for Placenta Previa

Not Applicable
Conditions
Placenta Previa
Interventions
Procedure: Foley's Catheter
Drug: Placebo
Registration Number
NCT03741114
Lead Sponsor
Aswan University Hospital
Brief Summary

Placenta previa (PP) is an obstetric condition that is closely linked with massive obstetric hemorrhage with a varied incidence about once in every 150-250 live births. Insertion of intrauterine balloon tamponade has been suggested in the management of massive postpartum hemorrhage (PPH). The Bakri balloon has a sausage-like spindle shape and a drainage lumen and is made of silicon. It has been used in cases of uterine atony and placenta previa with a success rate of 90%. However, Bakri balloon is not available in all countries.

The aim of this study is to evaluate the efficacy of the use of intrauterine inflated Foley's catheter balloon with or without intravenous tranexamic acid to control PPH during cesarean delivery in cases of placenta previa.

Detailed Description

Eligible participants were allocated to one of two groups. Group (I): patients managed by Intrauterine Inflated Foley's Catheter Balloon after delivery of the fetus. Group (II): patients received 1 gm tranexamic acid (TA), (2 ampoules of Capron® 500 mg /5 ml; Cairo, Egypt) intravenous just before skin incision plus Intrauterine Inflated Foley's Catheter Balloon. In group I, patients received a single injection of intravenous saline before skin incision prepared in a syringe and coded by a pharmacist in the pharmacy of the hospital. Neither the surgeon nor the anesthetist will know the nature of the IV administered drug before cesarean section.

Recruitment & Eligibility

Status
UNKNOWN
Sex
Female
Target Recruitment
120
Inclusion Criteria
  • all pregnant women with a single term fetus scheduled for an elective cesarean section for complete placenta previa
Exclusion Criteria
  • Patients with a cardiac, hepatic, renal or thromboembolic disease
  • patients with the high possibility of the morbid adherent placenta
  • known coagulopathy or thromboembolic disease
  • those presented with severe antepartum hemorrhage
  • hypersensitivity or contraindications of use of tranexamic acid
  • patient refuses to consent

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Foley's Catheter plus placebo to TAFoley's Catheterpatients managed by Intrauterine Inflated Foley's Catheter Balloon after delivery of the fetus plus single injection of 100 ml intravenous saline before skin incision
Foley's Catheter plus TAFoley's Catheterpatients managed by Intrauterine Inflated Foley's Catheter Balloon after delivery of the fetus plus 1 gm tranexamic acid in 100ml saline intravenous just before skin incision
Foley's Catheter plus placebo to TAPlacebopatients managed by Intrauterine Inflated Foley's Catheter Balloon after delivery of the fetus plus single injection of 100 ml intravenous saline before skin incision
Foley's Catheter plus TATApatients managed by Intrauterine Inflated Foley's Catheter Balloon after delivery of the fetus plus 1 gm tranexamic acid in 100ml saline intravenous just before skin incision
Primary Outcome Measures
NameTimeMethod
Number of Participants with postpartum hemorrhage24 hours post operative

number of participant with blood loss \> 1000ml

Secondary Outcome Measures
NameTimeMethod
intraoperative blood lossduring the operation

amount of blood loss during cesarean section

The number of participant needed for blood transfusion24 hours postoperative

Calculation of the number of participant needed for blood transfusion

number of participant need of extra surgical maneuvers24 hours post operative

number of participant need of extra surgical maneuvers like internal iliac ligation or hysterectomy

Trial Locations

Locations (1)

Aswan University

🇪🇬

Aswan, Egypt

© Copyright 2025. All Rights Reserved by MedPath